This led us to explore the use of zoledronate, a bisphosphonate drug that inhibits farnesyl diphosphate synthase to accumulate DMAPP and IPP, or a BTN3A1 agonistic antibody 20.1 to sensitize WAT primary glioma cells to Vγ9Vδ2 T cell killing. The gene discussed is FDPS; the disease is central nervous system cancer.